Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer

被引：7
|
作者：
Ecke, Thorsten H. [1 ]
机构：
[1] HELIOS Hosp, Dept Urol, Pieskower Str 33, D-15526 Bad Saarow Pieskow, Germany
来源：
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION | 2015年 / 867卷
关键词：
Adjuvant chemotherapy; Bax; Bcl-2; Biomarker; Bladder cancer; CD40; Chemotherapy; Cisplatin; C-reactive protein (CRP); Emmprin; ERCC1; HER2/neu; Human epidermal growth factor receptor 2 (HER-2); Ki-67; MDR1; Metallothionein (MT); p53; Smac/DIABLO; Survivin; Tissue polypeptide antigen (TPA); TLX3; gene; Transcription factor TFAP2 alpha; TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; TISSUE POLYPEPTIDE ANTIGEN; MESSENGER-RNA EXPRESSION; METASTATIC UROTHELIAL CARCINOMA; PROVIDE PROGNOSTIC INFORMATION; TYROSINE KINASE INHIBITORS; LONG-TERM SURVIVAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY;
D O I：
10.1007/978-94-017-7215-0_18
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The treatment of metastasized bladder cancer has been evolving during recent years. Cisplatin based chemotherapy combinations are still gold standard in the treatment of advanced and metastasized bladder cancer. But new therapies are approaching. Based to this fact biological markers will become more important for decisions in bladder cancer treatment. A systematic MEDLINE search of the key words "cisplatin", "bladder cancer", "DNA marker", "protein marker", "methylation biomarker", "predictive marker", "prognostic marker" has been made. This review aims to highlight the most relevant clinical and experimental studies investigating markers for metastasized transitional carcinoma of the urothelium treated by cisplatin based regimens.
引用
收藏
页码：293 / 316
页数：24
相关论文
共 50 条
  • [41] Choriocarcinoma of the gallbladderTreated with cisplatin-based chemotherapy
    Jen C. Wang
    Santos Angeles
    Peter Chak
    Ann B. Platt
    Nagabhushana Nimmagadda
    Medical Oncology, 2001, 18 : 165 - 169
  • [42] Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
    Keck, Bastian
    Wach, Sven
    Stoehr, Robert
    Kunath, Frank
    Bertz, Simone
    Lehmann, Jan
    Stoeckle, Michael
    Taubert, Helge
    Wullich, Bernd
    Hartmann, Arndt
    BMC CANCER, 2013, 13
  • [43] Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer
    Jin, James O.
    Lehmann, Jan
    Taxy, Jerome
    Huo, Dezheng
    Stokle, Michael
    Vogelzang, Nicholas J.
    Steinberg, Gary
    Stadler, Walter M.
    CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 150 - 154
  • [44] Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer
    Muramaki, Mototsugu
    Miyake, Hideaki
    Kurahashi, Toshifumi
    Takenaka, Atsushi
    Inoue, Taka-Aki
    Fujisawa, Masato
    INTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (04) : 314 - 318
  • [45] TISSUE MMP-7 EXPRESSION PREDICTS SURVIVAL IN BLADDER CANCER PATIENTS TREATED WITH CISPLATIN-BASED CHEMOTHERAPY
    Szarvas, Tibor
    Kramer, Gero
    Hess, Jochen
    Tschirdewahn, Stephan
    Reis, Henning
    Romics, Imre
    Sevcenco, Sabina
    Toetsch, Martin
    Ruebben, Herbert
    Dorp, Frank Vom
    JOURNAL OF UROLOGY, 2012, 187 (04): : E575 - E575
  • [46] Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
    Bastian Keck
    Sven Wach
    Robert Stoehr
    Frank Kunath
    Simone Bertz
    Jan Lehmann
    Michael Stöckle
    Helge Taubert
    Bernd Wullich
    Arndt Hartmann
    BMC Cancer, 13
  • [47] The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer
    Kim, Philip H.
    Kent, Matthew
    Zhao, Philip
    Sfakianos, John P.
    Bajorin, Dean F.
    Bochner, Bernard H.
    Dalbagni, Guido
    WORLD JOURNAL OF UROLOGY, 2014, 32 (02) : 453 - 459
  • [48] BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy
    Font, A.
    Taron, M.
    Costa, C.
    Layos, L.
    Perez-Roca, L.
    Sanchez, J.
    Chaib, I.
    Mora, M.
    Gago, J.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function
    Koshkin, Vadim S.
    Barata, Pedro C.
    Rybicki, Lisa A.
    Zahoor, Haris
    Almassi, Nima
    Redden, Alicia M.
    Fergany, Amr F.
    Kaouk, Jihad
    Haber, Georges-Pascal
    Stephenson, Andrew J.
    Ornstein, Moshe C.
    Gilligan, Timothy
    Garcia, Jorge A.
    Rini, Brian, I
    Grivas, Petros
    CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : E879 - E892
  • [50] Proportion of elderly patients with advanced bladder cancer receiving cisplatin-based chemotherapy: A large Medicare database study
    Chen, Guoqing J.
    Galsky, Matt D.
    Latini, David M.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345